Comprehensive 2025 CRISPR And Cas Gene Market Overview: Trends, Forecasts, and Growth Drivers

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the CRISPR And Cas Gene Market Through 2025?
The market size for CRISPR and Cas genes has seen an exponential increase in the past few years. The market is predicted to expand from a size of $3.99 billion in 2024 to $4.85 billion in 2025, depicting a compound annual growth rate (CAGR) of 21.7%. Key factors attributing to this considerable growth during the historical period include a heightened consumer awareness, changing consumer values, an increase in celebrity endorsements, the growing prevalence of veganism, and the pervasive influence of social media.

What's the Projected Size of the Global CRISPR And Cas Gene Market by 2029?
The market size for CRISPR and CAS gene is projected to witness substantial expansion in the forthcoming years, reaching $10.81 billion by 2029 with a compound annual growth rate (CAGR) of 22.2%. The anticipated growth during this period can be associated with worldwide bans extension, increasing conscious consumer behavior, entry of new brand players, initiatives to educate consumers and inclusivity in beauty. Key trends projected to influence this growth include advancements in technology, product innovation, the circular beauty economy, development in men's grooming sector and ethical sourcing while ensuring social justice.

View the full report here:
https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

Top Growth Drivers in the CRISPR And Cas Gene Industry: What's Accelerating the Market?
The expansion of the CRISPR and Cas gene markets is anticipated to be stimulated by an increasing emphasis on personalized therapy. This therapeutic model utilizes an individual's genetic makeup to guide decisions related to diagnosing, treating, and preventing diseases. CRISPR and Cas genes, especially Cas9, play a pivotal role in personalized medicine. They provide precise alterations to a person's genetic material, offering potential for revolutionary advances in creating targeted therapies for genetic abnormalities, cancer, and various health conditions. For example, in January 2023, as reported by the US-based professional society, the Personalized Medicine Coalition, the FDA's Center for Drug Evaluation and Research (CDER) authorized 37 new molecular entities (NMEs) in 2022. Out of these, around 34% or 12 NMEs, have been identified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the escalating demand for personalized therapy is expected to bolster the growth of the CRISPR and Cas gene markets.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13632&type=smp

What Trends Will Shape the CRISPR And Cas Gene Market Through 2029 and Beyond?
Leading companies in the CRISPR and Cas gene markets are innovating and producing products such as CRISPR-based cell-based gene therapy to broaden their product range and secure a competitive edge. CRISPR-based cell-based gene therapy utilizes CRISPR gene-editing technology to adjust or correct genetic material inside cells, offering a focused and potentially groundbreaking method for managing genetic disorders, diseases, and other cellular-level medical conditions. For example, in December 2023, Vertex Pharmaceuticals Incorporated, a biopharmaceutical company based in the US, gained approval for CASGEVY (exagamglogene autotemcel [exa-cel]) from the U.S. Food and Drug Administration (FDA). CASGEVY, a CRISPR/Cas9 genome-edited gene therapy, is used to treat sickle cell disease (SCD) in individuals aged 12 and older who frequently suffer from vaso-occlusive crises. As the first medication of its kind, CASGEVY has the potential to be a game-changing, one-time therapy for eligible sickle cell patients. The administration of CASGEVY needs specialized training in stem cell transplantation, therefore, Vertex is partnering with expert institutions to establish a network of independently owned, approved treatment centers (ATCs) throughout the United States to deliver CASGEVY to patients.

What Are the Main Segments in the CRISPR And Cas Gene Market?
The crispr and cas gene market covered in this report is segmented -

1) By Product Type: Kits And Enzymes, Libraries, Design Tool, Antibodies, Other Products Types
2) By Service Type: Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis
3) By Application: Clinical, Financial, Operational And Administrative
4) By End Use: Biotechnology And Pharmaceutical Companies, Academics And Government Research Institutes, Contract Research Organizations (CROs)

Subsegments:
1) By Kits And Enzymes: CRISPR Kits, Cas Enzymes, Grna Synthesis Kits
2) By Libraries: CRISPR Libraries For Gene Knockout, CRISPR Libraries For Gene Activation, Sgrna Libraries
3) By Design Tools: Online Design Platforms, Software For CRISPR Guide RNA Design, Custom Design Services
4) By Antibodies: Antibodies For Cas Proteins, Antibodies For Detection Of Edited Cells, Secondary Antibodies For Immunoassays
5) By Other Product Types: Delivery Systems, CRISPR-Related Consumables, Control Plasmids And Reagents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13632&type=smp

Which Top Companies are Driving Growth in the CRISPR And Cas Gene Market?
Major companies operating in the Crispr and cas gene market report are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., AstraZeneca plc., Danaher Corporation, Quest Diagnostics, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, Myriad Genetics Inc., GenScript, Takara Bio Inc., 23andMe Inc., Merck KGaA, Color Genomics Inc., Horizon Discovery Group PLC, Beam Therapeutics Inc., Intellia Therapeutics Inc., New England BioLabs, Recursion Pharmaceuticals Inc., Caribou Biosciences Inc., Cellectis S.A., Editas Medicine Inc.

Which Regions Will Dominate the CRISPR And Cas Gene Market Through 2029?
North America was the largest region in the CRISPR and Cas gene market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CRISPR and cas gene market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13632

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.